Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fastly Inc (FSLY) vs Pfizer Inc (PFE) Price & Performance

Fastly IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Fastly Inc vs Pfizer Inc — how do they compare? Fastly Inc trades at $28.28 (market cap $4.03B), while Pfizer Inc trades at $27.86 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 39.3× Fastly Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Fastly Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Pfizer Inc for 158 Days on average.

FSLYPFE
Market Cap
$4.03B$158.56B
Volume
5,516,49544,138,282
Sector
TechnologyHealth
52-Week High
$33.50$29.02
52-Week Low
$7.86$23.67
Typical Hold Time
26 Days158 Days
Enterprise Value
$4.09B$210.06B
Dividend Yield
—6.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fastly Inc

Fastly (FSLY) trades at $25.28, down 0.9% on the day, amid mixed technical and fundamental signals. The stock exhibits a bullish technical trend with support near $25, while recent earnings have consistently beaten expectations. Revenue growth is robust, projected to reach $687 million in 2026, but profitability remains elusive with a net income margin of -11.8%. The company's strategic focus on AI and edge cloud infrastructure, highlighted during its recent Investor Day, fuels optimism for long-term growth.

The investment outlook for FSLY balances strong revenue expansion and AI-driven opportunities against persistent losses and insider selling. While analyst consensus leans neutral with a $28.25 price target, the stock's valuation appears stretched relative to earnings. Key risks include competitive pressures in edge computing and the need to translate top-line growth into sustainable profitability. Investors should weigh the company's growth trajectory against its current financial health.

Pfizer Inc

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FSLY
0% Buy100% Sell
Avg holding period · 26 Days
PFE
70% Buy30% Sell
Avg holding period · 158 Days

Top news

Latest headlines on both assets

About Fastly Inc

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.

Read more on FSLY →

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE →